Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 18.50
Change Today -0.20 / -1.07%
Volume 517.2K
BOLT On Other Exchanges
Symbol
Exchange
Tel Aviv
OTC US
As of 10:24 AM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

bio light israeli life scien (BOLT) Snapshot

Open
$18.70
Previous Close
$18.70
Day High
$18.70
Day Low
$18.20
52 Week High
10/6/14 - $20.40
52 Week Low
09/28/14 - $13.10
Market Cap
119.3M
Average Volume 10 Days
839.2K
EPS TTM
$-0.04
Shares Outstanding
644.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIO LIGHT ISRAELI LIFE SCIEN (BOLT)

Related News

No related news articles were found.

bio light israeli life scien (BOLT) Related Businessweek News

No Related Businessweek News Found

bio light israeli life scien (BOLT) Details

BioLight Israeli Life Sciences Investments Ltd. engages in the research and development, and commercialization of biomed solutions. The company operates through Ophthalmology and Cancer Cell Diagnostics. The Ophthalmology segment develops and markets a nonpenetrating CO2 laser assisted filtration surgery technology for treating glaucoma; researches and develops a sub-conjunctival drug insert technology for the controlled release of ophthalmic medications; and develops a product for diagnosis, diagonsic, and monitoring of dry eye syndrome by examining the composition of the tear fluid. The Cancer Cell Diagnostics segment is developing medical solutions for cancer diagnostics. It develops CellDetect, a diagnostic technology for the staining and detection of cancer and pre-cancer cells with various cancer indications. This segment is also engages in the developing and commercializing a predictive genetic test for identification of individuals with bisphosphonate related osteonecrosis of the jaw; participating in the funding of the NCBI's Nofar study of predictive biochemical-markers for the development of brain metastases from lung cancer; development of an innovative diagnostic kit for identifying carriers of deletrious BRCA mutations, who are at increase the risk of breast and ovarian cancers; and research and development, and marketing of a diagnostic kit for early identification of CRC using a q-PCR based blood test. BioLight Israeli Life Sciences Investments Ltd. was founded in 2005 and is based in Tel Aviv, Israel.

Founded in 2005

bio light israeli life scien (BOLT) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: 807.0K
Chief Financial Officer
Total Annual Compensation: 582.0K
Compensation as of Fiscal Year 2014.

bio light israeli life scien (BOLT) Key Developments

BioLight Life Sciences Investments Expands Relationship with Ora, Inc. to Advance the Clinical, Regulatory and Commercial Development of BioLight's TeaRx

BioLight Life Sciences Investments announced that it has expanded its relationship with Ora, Inc., via the signing of a Collaboration Agreement pursuant to which the companies will work together to advance the clinical, regulatory and commercial development of BioLight's TeaRx multi-parameter diagnostic test for dry eye syndrome. While financial terms were not disclosed, BioLight advised that, the company and Ora will jointly fund the clinical study and other activities required to obtain USD 510,000 regulatory approval for the TeaRx multi-parameter diagnostic test for DES. BioLight also granted Ora the right to incorporate the TeaRx test in other clinical trials sponsored by third parties and performed by Ora.

Bio Light Israeli Life Sciences Investments Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2015

Bio Light Israeli Life Sciences Investments Ltd. reported earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues were NIS 157,000. The net loss for the first quarter of 2015 was approximately NIS 6.6 million or NIS 0.01 loss per share, as compared to a net loss of approximately NIS 7.8 million, or NIS 0.02 loss per share, for first quarter of 2014.

Bio Light Israeli Life Sciences Investments Ltd. Announces First IOPtiMate System Sale in Hungary

Bio Light Israeli Life Sciences Investments Ltd. announced the first sale of the IOPtiMate system to a medical center located in Hungary. The IOPtiMate system is based on CO2 laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball, thus allowing for substantial reductions in post-operative complications and use of eye drops compared with alternatives. BioLight recently announced a strategic partnership agreement with Rock-One International Holdings Ltd. The agreement will help BioLight maximize its presence in the Chinese market.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BOLT:IT 18.50 -0.20

BOLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BOLT.
View Industry Companies
 

Industry Analysis

BOLT

Industry Average

Valuation BOLT Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO LIGHT ISRAELI LIFE SCIEN, please visit www.bio-light.co.il. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.